Covid-19 vac­cine boost­ers earn big thumbs up, but Mod­er­na draws ire over world sup­ply; What's next for Mer­ck’s Covid pill?; The C-suite view on biotech; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

You may re­mem­ber that at the be­gin­ning of this year, End­points News set a goal to go broad­er and deep­er. We are still work­ing to­wards that, and are ex­cit­ed to share that Beth Sny­der Bu­lik will be join­ing us on Mon­day to cov­er all things phar­ma mar­ket­ing. You can sign up for her week­ly End­points Mar­ket­ingRx newslet­ter in your read­er pro­file.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER